(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 November 2021 (11.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/226477 A1

(51) International Patent Classification:
A61K 31/167 (2006.01) *C07D 401/14* (2006.01)
A61K 31/4709 (2006.01)

(21) International Application Number:
PCT/US2021/031325

(22) International Filing Date:
07 May 2021 (07.05.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/021,987 08 May 2020 (08.05.2020) US
63/121,001 03 December 2020 (03.12.2020) US

(71) Applicant: **GEORGIAMUNE LLC** [US/US]; 13408 Hathaway Drive, Silver Spring, MD 30904 (US).

(72) Inventors; and
(71) Applicants: **KHLEIF, Samir** [US/US]; 613 Brookes Ridge Ct., Bethesda, MD 20816 (US). **MKRTICHYAN, Mikayel** [US/US]; 9450 Tujunga Canyon Blvd., Tujunga, CA 91042 (US).

(72) Inventor: **MACCOSS, Malcolm**; 2556 Seabrook Island Road, Seabrook Island, SC 29455 (US).

(74) Agent: **SUPERKO, Colleen** et al.; Wilmer Cutler Pickering Hale and Dorr LLP, 60 State Street, Boston, MA 02109 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

WO 2021/226477 A1

(54) Title: AKT3 MODULATORS



Figure 1



(57) Abstract: Compounds of Formula Ia, Ib, or Ic, Formula (Ia); Formula (Ib); or Formula (Ic), are described, where the various substituents are defined herein. The compounds can modulate a property or effect of Akt3 *in vitro* or *in vivo*, and can also be used, individually or in combination with other agents, in the prevention or treatment of a variety of conditions. Methods for synthesizing the compounds are described. Pharmaceutical compositions and methods of using these compounds or compositions, individually or in combination with other agents or compositions, in the prevention or treatment of a variety of conditions are also described.

[Continued on next page]

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*